Allarity Acquisition, a blank check company backed by Allarity Therapeutics and focused on the life sciences and biotechnology sectors, has reduced the proposed size of its upcoming initial public offering by 20%. The Tarpon Springs, Florida-based SPAC now plans to raise $80 million, down from its previous proposal of $100 million.
Reduced IPO Size
Allarity Acquisition now plans to offer 8 million units at $10 per unit, compared with its earlier filing for 10 million units at the same price. The reduction lowers the proposed deal size by $20 million, or 20%.
Each unit will consist of one share of common stock and one whole warrant. Each warrant will provide the holder with the right to purchase one additional share at an exercise price of $11.50.
The smaller offering means the SPAC will enter the public markets with a lower initial capital base while maintaining the same unit price and warrant structure outlined in its previous filing.
Life Sciences and Biotechnology Focus
Allarity Acquisition intends to search for a business combination in the life sciences and biotechnology sectors. As a blank check company, its primary purpose is to raise capital through the IPO and subsequently identify a target for a potential business combination.
The company is backed by executives with existing experience in biotechnology and healthcare companies, aligning its leadership structure with the sectors it intends to target.
Management Team
Allarity Acquisition is led by Thomas Jensen, CEO and co-founder of Allarity Therapeutics, who serves as chief executive officer of the SPAC.
Jeffrey Ervin, CFO of Allarity Therapeutics, serves as chief financial officer, while Jesper Hoiland, Head of Strategy at Rani Therapeutics, serves as chairman.
The management team’s existing connections to publicly traded biotechnology companies could provide sector-specific experience as Allarity Acquisition evaluates potential targets.
IPO and Nasdaq Listing Details
Allarity Acquisition was founded in 2026 and plans to list its units on the Nasdaq under the symbol ALLNU.
Maxim Group LLC is serving as the sole bookrunner for the offering.
The proposed IPO will provide the SPAC with $80 million in gross proceeds if all 8 million units are sold at the stated $10 offering price. The source does not provide additional details regarding the timing of the offering or the specific terms of a future business combination.
Market Context & Opportunities
The reduced offering gives Allarity Acquisition a smaller pool of capital with which to pursue a life sciences or biotechnology target. Its management team’s existing experience in the sector could be relevant as the SPAC evaluates potential companies and opportunities for a combination.
The inclusion of a whole warrant with each unit also provides investors with additional potential exposure to the eventual combined company if the warrants become exercisable.
Risks & Challenges
As with other SPACs, Allarity Acquisition must identify an appropriate acquisition target and successfully complete a business combination before investors gain exposure to an operating company. The eventual target, valuation and transaction structure remain unknown at this stage.
The 20% reduction in the proposed IPO size also means the SPAC will have less initial capital available for a future transaction than contemplated in its earlier filing. Investors will therefore need to evaluate the eventual target and transaction terms once they are disclosed.
Closing Paragraph
Allarity Acquisition has reduced its proposed IPO by 20% to $80 million, with plans to sell 8 million units at $10 each. With a whole warrant attached to every unit and a stated focus on life sciences and biotechnology, the SPAC is positioning itself to pursue a sector-specific acquisition under the leadership of executives with existing biotechnology industry experience.
